NASDAQ:BPMX - BioPharmX News Headlines

Sign in or create an account to add this stock to your watchlist.
$0.1151 0.00 (0.00 %)
(As of 01/18/2019 04:00 PM ET)
Previous Close$0.1151
Today's Range$0.1140 - $0.12
52-Week Range$0.05 - $0.38
Volume2.43 million shs
Average Volume6.41 million shs
Market CapitalizationN/A
P/E RatioN/A
Dividend YieldN/A
BetaN/A

Headlines

BioPharmX (NASDAQ BPMX) News Headlines

Source:
DateHeadline
-$0.02 Earnings Per Share Expected for BioPharmX Corporation (BPMX) This Quarter-$0.02 Earnings Per Share Expected for BioPharmX Corporation (BPMX) This Quarter
www.americanbankingnews.com - January 10 at 7:23 PM
Analysts Expect BioPharmX Corporation (BPMX) to Announce ($0.02) EPSAnalysts Expect BioPharmX Corporation (BPMX) to Announce ($0.02) EPS
www.americanbankingnews.com - January 3 at 3:44 AM
BioPharmX Corp.BioPharmX Corp.
www.barrons.com - December 21 at 3:15 PM
Active-Investors: Free Post Earnings Research Report: BioPharmXs Adjusted EPS Beat ExpectationsActive-Investors: Free Post Earnings Research Report: BioPharmX's Adjusted EPS Beat Expectations
www.finanznachrichten.de - January 9 at 8:24 AM
Free Post Earnings Research Report: BioPharmX’s Adjusted EPS Beat ExpectationsFree Post Earnings Research Report: BioPharmX’s Adjusted EPS Beat Expectations
finance.yahoo.com - January 9 at 8:24 AM
How BioPharmX Corporation’s (NYSEMKT:BPMX) EPS Growth Stacks Up Against Industry PerformanceHow BioPharmX Corporation’s (NYSEMKT:BPMX) EPS Growth Stacks Up Against Industry Performance
finance.yahoo.com - December 16 at 8:18 AM
Blog Exposure - MabVax Therapeutics Completes Enrollment and Dosing In Initial Cohort of Phase-1 Trial of Its Cancer Drug MVT-1075Blog Exposure - MabVax Therapeutics Completes Enrollment and Dosing In Initial Cohort of Phase-1 Trial of Its Cancer Drug MVT-1075
finance.yahoo.com - December 15 at 8:15 AM
ETFs with exposure to BioPharmX Corp. : December 1, 2017ETFs with exposure to BioPharmX Corp. : December 1, 2017
finance.yahoo.com - December 1 at 4:04 PM
Health Care Sector Update for 11/21/2017: ARDX,CLSN,BPMX - NasdaqHealth Care Sector Update for 11/21/2017: ARDX,CLSN,BPMX - Nasdaq
www.nasdaq.com - November 22 at 12:30 AM
BioPharmX (BPMX) Prices 73.5M Share Common Offering at $0.15/ShBioPharmX (BPMX) Prices 73.5M Share Common Offering at $0.15/Sh
www.streetinsider.com - November 21 at 7:29 PM
Health Care Sector Update for 11/21/2017: KTOV,CLSN,BPMX - NasdaqHealth Care Sector Update for 11/21/2017: KTOV,CLSN,BPMX - Nasdaq
www.nasdaq.com - November 21 at 2:28 PM
BioPharmX prices equity offering; shares down 35% premarket - Seeking AlphaBioPharmX prices equity offering; shares down 35% premarket - Seeking Alpha
seekingalpha.com - November 21 at 2:28 PM
BioPharmX Corporation Announces Pricing of Public OfferingBioPharmX Corporation Announces Pricing of Public Offering
finance.yahoo.com - November 21 at 2:28 PM
After-Hours Stock Movers 05/03: (FIVN) (FORM) (DATA) Higher; (BPMX) (LNTH) (CAKE) Lower (more...)After-Hours Stock Movers 05/03: (FIVN) (FORM) (DATA) Higher; (BPMX) (LNTH) (CAKE) Lower (more...)
www.streetinsider.com - May 3 at 9:06 PM
BioPharmX (BPMX) Expects Topline Results from Phase 2b Trial of BPX-01 in First Half of May 2017BioPharmX (BPMX) Expects Topline Results from Phase 2b Trial of BPX-01 in First Half of May 2017
www.streetinsider.com - April 20 at 4:08 PM
BioPharmX to Report Fourth Quarter and Full Year Financial Results - PR Newswire (press release)BioPharmX to Report Fourth Quarter and Full Year Financial Results - PR Newswire (press release)
www.prnewswire.com - March 16 at 3:49 PM
BioPharmX completes enrollment in mid-stage study of acne treatment BPX-01; shares up 5%BioPharmX completes enrollment in mid-stage study of acne treatment BPX-01; shares up 5%
seekingalpha.com - January 4 at 12:26 PM
BIOPHARMX CORP Files SEC form 8-K, Entry into a Material Definitive Agreement, Financial Statements and ExhibitsBIOPHARMX CORP Files SEC form 8-K, Entry into a Material Definitive Agreement, Financial Statements and Exhibits
biz.yahoo.com - December 20 at 5:14 AM
BIOPHARMX CORP Files SEC form 8-K, Results of Operations and Financial Condition, Change in Directors or Principal OfBIOPHARMX CORP Files SEC form 8-K, Results of Operations and Financial Condition, Change in Directors or Principal Of
biz.yahoo.com - December 13 at 9:41 PM
9:07 am BioPharmX will present research findings this week that suggest topical minocycline fights P. acnes-induced inflammation in human keratinocytes9:07 am BioPharmX will present research findings this week that suggest topical minocycline fights P. acnes-induced inflammation in human keratinocytes
us.rd.yahoo.com - December 1 at 9:04 PM
BioPharmX closes unit offeringBioPharmX closes unit offering
seekingalpha.com - November 30 at 4:00 PM
BioPharmX Pivot Means Its Time To WaitBioPharmX Pivot Means It's Time To Wait
seekingalpha.com - November 22 at 9:35 PM
BioPharmX (BPMX) Prices Net $11.7M Unit OfferingBioPharmX (BPMX) Prices Net $11.7M Unit Offering
www.streetinsider.com - November 22 at 9:35 PM
BioPharmX prices equity offeringBioPharmX prices equity offering
seekingalpha.com - November 22 at 9:21 AM
BioPharmX (BPMX) Enters 1.55M Share Stock Sales AgreementBioPharmX (BPMX) Enters 1.55M Share Stock Sales Agreement
www.streetinsider.com - September 28 at 3:43 PM
BIOPHARMX CORP Files SEC form 8-K, Entry into a Material Definitive Agreement, Unregistered Sale of Equity SecuritiesBIOPHARMX CORP Files SEC form 8-K, Entry into a Material Definitive Agreement, Unregistered Sale of Equity Securities
biz.yahoo.com - September 28 at 8:41 AM
BioPharmX (BPMX) Q2 2016 Results - Earnings Call TranscriptBioPharmX (BPMX) Q2 2016 Results - Earnings Call Transcript
seekingalpha.com - September 13 at 8:48 AM
Biopharmx (BPMX) Pops as Loss LoomsBiopharmx (BPMX) Pops as Loss Looms
www.baystreet.ca - September 12 at 3:50 PM
Mfg., Housing Figures Due Next WeekMfg., Housing Figures Due Next Week
www.baystreet.ca - September 10 at 8:39 AM
BioPharmX (BPMX) Announces First Subject Enrolled in OPAL Phase 2b Trial of BPX-01BioPharmX (BPMX) Announces First Subject Enrolled in OPAL Phase 2b Trial of BPX-01
www.streetinsider.com - August 24 at 12:11 PM
BioPharmX (BPMX) Announces Statistically Significant Data from BPX-01 Phase 2aBioPharmX (BPMX) Announces Statistically Significant Data from BPX-01 Phase 2a
www.streetinsider.com - August 22 at 8:44 AM
BIOPHARMX CORP Files SEC form 8-K, Entry into a Material Definitive Agreement, Creation of a Direct Financial ObligatBIOPHARMX CORP Files SEC form 8-K, Entry into a Material Definitive Agreement, Creation of a Direct Financial Obligat
biz.yahoo.com - August 18 at 12:21 PM
BioPharmX Reveals Positive Topline Phase 2a Clinical Trial Results For BPX-01BioPharmX Reveals Positive Topline Phase 2a Clinical Trial Results For BPX-01
feeds.benzinga.com - June 29 at 12:39 PM
BioPharmX Announces Positive Topline Phase 2a Clinical Trial Results for BPX-01 in Patients with Acne-Causing BacteriaBioPharmX Announces Positive Topline Phase 2a Clinical Trial Results for BPX-01 in Patients with Acne-Causing Bacteria
www.prnewswire.com - June 29 at 12:15 PM
BioPharmX (BPMX) Q1 2016 Results - Earnings Call TranscriptBioPharmX (BPMX) Q1 2016 Results - Earnings Call Transcript
seekingalpha.com - June 15 at 8:51 AM
BIOPHARMX CORP Files SEC form 8-K, Change in Directors or Principal Officers, Other Events, Financial Statements andBIOPHARMX CORP Files SEC form 8-K, Change in Directors or Principal Officers, Other Events, Financial Statements and
biz.yahoo.com - May 12 at 5:16 PM
BIOPHARMX CORP Files SEC form 10-K, Annual ReportBIOPHARMX CORP Files SEC form 10-K, Annual Report
biz.yahoo.com - May 2 at 4:11 PM
Earnings Reported After The Bell Apr. 26Earnings Reported After The Bell Apr. 26
www.rttnews.com - April 27 at 1:05 PM
BioPharmX Corporation misses by $0.01BioPharmX Corporation misses by $0.01
seekingalpha.com - April 26 at 4:41 PM
Q4 2015 BioPharmX Corp Earnings Release - After Market CloseQ4 2015 BioPharmX Corp Earnings Release - After Market Close
biz.yahoo.com - April 26 at 7:07 AM
This page was last updated on 1/19/2019 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.

Yahoo Gemini Pixel